CS Cancer Solutions - Structured Oncology Intelligence

Iowa Cancer Research Ecosystem | Population Science & Epidemiology

Iowa Research Ecosystem

Iowa Cancer Research — Population Science & Epidemiology

Understanding oncology research within Iowa's population science and translational research ecosystem, including the Holden Comprehensive Cancer Center

Purpose & Educational Context

This page provides an educational overview of oncology research in Iowa, with emphasis on the state's population science and translational research ecosystem and the Holden Comprehensive Cancer Center.

This page does not provide medical advice, treatment recommendations, care navigation, or referral services.

Holden CCC
NCI-Designated Center
Population Science
Research Focus
Research Focus
Epidemiology
Active
Precision Medicine

Population & Regional Context

Iowa's oncology research ecosystem emphasizes population-based studies, cancer surveillance, and translation of epidemiologic findings into prevention and early detection research.

NCI-Designated Cancer Center

Iowa's comprehensive cancer research infrastructure

Holden Comprehensive Cancer Center (University of Iowa)

NCI-Designated Comprehensive Cancer Center

Holden Comprehensive Cancer Center at the University of Iowa is Iowa's NCI-designated comprehensive cancer center and serves as a central hub for population science, cancer epidemiology, and precision oncology research.

Research Focus

  • •NCI-designated comprehensive cancer center
  • •Population science research
  • •Cancer epidemiology research
  • •Precision oncology research

Research Contribution

Holden CCC supports Iowa's oncology research ecosystem through population science and epidemiological research.

Visit Website

Stay Informed About Iowa Cancer Research

Get updates on Iowa-based oncology research and clinical trials.

We respect your privacy. No medical information required.

Explore More Research Resources

Access research context across U.S. states and globally

Latest Research Ecosystem Developments

Iowa — Iowa is significantly expanding its oncology research infrastructure and clinical trial capacity through the launch of the CANDID institute and continued leadership in specialized cancer research.

Updated October 18, 2026

Launch of the Institute for Cancer Drug Discovery and Development (CANDID)

The University of Iowa Board of Regents approved the creation of the CANDID institute, a partnership between the College of Pharmacy and Holden Comprehensive Cancer Center designed to accelerate the translation of laboratory discoveries into early-phase clinical trials.

University of Iowa College of Pharmacy

Renewal of Specialized Program of Research Excellence (SPORE) for Neuroendocrine Tumors

Holden Comprehensive Cancer Center was awarded a five-year, $10.7 million grant from the National Cancer Institute to continue its specialized research into neuroendocrine tumors, remaining the only institution in the U.S. to receive this specific federal funding.

University of Iowa

Leadership in Personalized Melanoma Vaccine Trials

UI Health Care served as one of the first national sites to participate in a phase 3 clinical trial for a personalized cancer vaccine developed by Moderna and Merck, which aims to prevent the recurrence of advanced melanoma.

Holden Comprehensive Cancer Center

Advancements in Oncolytic Virus and Immunotherapy Research

Researchers at UI Health Care, led by Dr. Mohammed Milhem, have been at the forefront of clinical trials combining oncolytic viruses with immunotherapies to improve outcomes for patients with metastatic melanoma.

Holden Comprehensive Cancer Center

Breakthroughs in DIPG and Cancer Genome Research

University of Iowa researchers have made significant strides in understanding cancer biology, including uncovering enzymes that reshape cancer genomes and developing new approaches to overcome treatment resistance in diffuse intrinsic pontine glioma (DIPG).

Holden Comprehensive Cancer Center

This section is refreshed on a recurring schedule. Entries are AI-assisted research signals organized from public oncology sources and should be verified against the original sources. Information is educational and does not constitute medical advice.

Huippu Prodigy Platforms

© 2026 Huippu Prodigy Platforms, LLC.

CS Cancer Solutions is operated by Huippu Prodigy Platforms, LLC.

Public-Source Oncology Research • Educational and Research Use

Structured Oncology Research Intelligence